Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rocket Pharmaceuticals (RCKT) Research & Development: 2013-2024

Historic Research & Development for Rocket Pharmaceuticals (RCKT) over the last 12 years, with Dec 2024 value amounting to $171.2 million.

  • Rocket Pharmaceuticals' Research & Development fell 19.49% to $34.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $150.0 million, marking a year-over-year decrease of 14.58%. This contributed to the annual value of $171.2 million for FY2024, which is 8.10% down from last year.
  • As of FY2024, Rocket Pharmaceuticals' Research & Development stood at $171.2 million, which was down 8.10% from $186.3 million recorded in FY2023.
  • In the past 5 years, Rocket Pharmaceuticals' Research & Development registered a high of $186.3 million during FY2023, and its lowest value of $105.4 million during FY2020.
  • Over the past 3 years, Rocket Pharmaceuticals' median Research & Development value was $171.2 million (recorded in 2024), while the average stood at $174.4 million.
  • In the last 5 years, Rocket Pharmaceuticals' Research & Development spiked by 82.08% in 2020 and then dropped by 8.10% in 2024.
  • Over the past 5 years, Rocket Pharmaceuticals' Research & Development (Yearly) stood at $105.4 million in 2020, then rose by 19.00% to $125.5 million in 2021, then skyrocketed by 31.95% to $165.6 million in 2022, then climbed by 12.55% to $186.3 million in 2023, then dropped by 8.10% to $171.2 million in 2024.